SCLX (Scilex Holding Co) Debt-to-Asset : 1.02 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co Debt-to-Asset?

Scilex Holding Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $76.07 Mil. Scilex Holding Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $30.93 Mil. Scilex Holding Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $104.54 Mil. Scilex Holding Co's debt to asset for the quarter that ended in Jun. 2024 was 1.02.

Scilex Holding Co Debt-to-Asset Historical Data

The historical data trend for Scilex Holding Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co Debt-to-Asset Chart

Scilex Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

1.70

1.99

0.02

1.27

Scilex Holding Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial								0.30	1.56	1.27	1.23	1.02

Competitive Comparison of Scilex Holding Co's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Scilex Holding Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's Debt-to-Asset falls into.

Scilex Holding Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Scilex Holding Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(109.188	+	19.275)	/	101.309
	=	1.27

Scilex Holding Co's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(76.071	+	30.926)	/	104.544
	=	1.02

Scilex Holding Co (NAS:SCLX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Scilex Holding Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Scilex Holding Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

960 San Antonio Road, Palo Alto, CA, USA, 94303

Website

https://www.scilexholding.com

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Executives

Henry Ji	director, officer: Executive Chairperson	5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah	director, officer: See Remarks	C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Jay Chun	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Dorman Followwill	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
David Lemus	director	C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Stephen Hoi Ma	officer: Chief Financial Officer	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sclx Stock Acquisition Jv Llc	10 percent owner	960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee	director	C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc.	10 percent owner	4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Elizabeth Czerepak	officer: See Remarks	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Steve Myint	director	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632
Chris Ho	director, 10 percent owner, officer: Chief Financial Officer	C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632